CLB Stock Analysis: Core Laboratories | NYSE
Oil & Gas Equipment & Services | NYSE, USA | Market Cap: 511m USD | 12M Return: -12.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.4M
EPS Trend: -49.1%
Qual. Beats: -1
Rev. Trend: 83.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Core Laboratories (NYSE: CLB) is a Houston-based provider of reservoir description and production enhancement services to the oil and gas industry, operating domestically and internationally since its founding in 1936. The company is organized into two segments: Reservoir Description, which offers laboratory-based analytical and field services to characterize reservoir rock and fluids, and Production Enhancement, which provides services and products for well completions, perforations, stimulations, production, and well abandonment. Within the broader Energy sector (GICS sub-industry: Oil & Gas Equipment & Services), CLB supplies specialized technical inputs to upstream exploration and production operators rather than producing hydrocarbons itself.
In addition to its core oil and gas offerings, Core Laboratories extends its reservoir analysis capabilities into adjacent areas such as carbon capture, utilization and storage (CCUS), geothermal energy projects, and mining evaluation, reflecting how oilfield services firms increasingly apply subsurface expertise to energy transition applications. The company markets its products and services through a multi-channel approach combining direct sales representatives, technical seminars, trade shows, print advertising, and third-party distributors.
- Global E&P capital spending drives Reservoir Description segment revenue
- Crude oil prices and U.S. completions activity boost Production Enhancement demand
- Energy transition services in CCUS and geothermal expand revenue mix
- Share repurchases and dividends support capital return to shareholders
| Net Income: 29.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -4.21 > 1.0 |
| NWC/Revenue: 20.89% < 20% (prev 24.15%; Δ -3.25% < -1%) |
| CFO/TA 0.06 > 3% & CFO 35.1m > Net Income 29.0m |
| Net Debt (198.4m) to EBITDA (72.4m): 2.74 < 3 |
| Current Ratio: 2.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.1m) vs 12m ago -1.50% < -2% |
| Gross Margin: 17.84% > 18% (prev 16.91%; Δ 0.93% > 0.5%) |
| Asset Turnover: 88.99% > 50% (prev 87.54%; Δ 1.46% > 0%) |
| Interest Coverage Ratio: 4.97 > 6 (EBIT TTM 53.9m / Interest Expense TTM 10.9m) |
| A: 0.19 (Total Current Assets 214.4m - Total Current Liabilities 104.7m) / Total Assets 587.7m |
| B: 0.29 (Retained Earnings 171.4m / Total Assets 587.7m) |
| C: 0.09 (EBIT TTM 53.9m / Avg Total Assets 589.6m) |
| D: 0.86 (Book Value of Equity 268.9m / Total Liabilities 312.6m) |
| Altman-Z'' = 3.69 = AA |
| DSRI: 0.87 (Receivables 115.2m/131.0m, Revenue 524.7m/517.8m) |
| GMI: 0.95 (GM 16.91% / 17.84%) |
| AQI: 1.00 (AQ_t 0.35 / AQ_t-1 0.35) |
| SGI: 1.01 (Revenue 524.7m / 517.8m) |
| TATA: -0.01 (NI 29.0m - CFO 35.1m) / TA 587.7m) |
| Beneish M = -3.17 (Cap -4..+1) = AA |
As of July 09, 2026, the stock is trading at USD 11.15 with a total of 793,781 shares traded. Over the past week, the price has changed by -4.29%, over one month by -16.98%, over three months by -33.42% and over the past year by -12.50%.
Current recommended Stop Loss: 10.30 (which is 7.6% or 1.4 ATR below the current price).
Core Laboratories has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold CLB.
- StrongBuy: 0
- Buy: 1
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 15.8 | 42% |
P/E Trailing = 18.1803
P/E Forward = 17.1821
P/S = 0.9742
P/B = 1.9647
P/EG = 1.4441
Revenue TTM = 524.7m USD
EBIT TTM = 53.9m USD
EBITDA TTM = 72.4m USD
Long Term Debt = 114.5m USD (from longTermDebt, last quarter)
Short Term Debt = 12.1m USD (from shortTermDebt, last quarter)
Debt = 221.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 53.4m
Net Debt = 198.4m USD (calculated: Debt 221.2m - CCE 22.8m)
Enterprise Value = 709.6m USD (511.2m + Debt 221.2m - CCE 22.8m)
Interest Coverage Ratio = 4.97 (Ebit TTM 53.9m / Interest Expense TTM 10.9m)
EV/FCF = 37.47x (Enterprise Value 709.6m / FCF TTM 18.9m)
FCF Yield = 2.67% (FCF TTM 18.9m / Enterprise Value 709.6m)
FCF Margin = 3.61% (FCF TTM 18.9m / Revenue TTM 524.7m)
Net Margin = 5.53% (Net Income TTM 29.0m / Revenue TTM 524.7m)
Gross Margin = 17.84% ((Revenue TTM 524.7m - Cost of Revenue TTM 431.1m) / Revenue TTM)
Gross Margin QoQ = 16.19% (prev 18.13%)
Tobins Q-Ratio = 1.21 (Enterprise Value 709.6m / Total Assets 587.7m)
Interest Expense / Debt = 4.91% (Interest Expense 10.9m / Debt 221.2m)
Taxrate = 31.36% (13.5m / 43.1m)
NOPAT = 37.0m (EBIT 53.9m * (1 - 31.36%))
Current Ratio = 2.05 (Total Current Assets 214.4m / Total Current Liabilities 104.7m)
Debt / Equity = 0.82 (Debt 221.2m / totalStockholderEquity, last quarter 268.9m)
Debt / EBITDA = 2.74 (Net Debt 198.4m / EBITDA 72.4m)
Debt / FCF = 10.48 (Net Debt 198.4m / FCF TTM 18.9m)
Total Stockholder Equity = 266.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.92% (Net Income 29.0m / Total Assets 587.7m)
RoE = 10.88% (Net Income TTM 29.0m / Total Stockholder Equity 266.9m)
RoCE = 14.14% (EBIT 53.9m / Capital Employed (Equity 266.9m + L.T.Debt 114.5m))
RoIC = 7.84% (NOPAT 37.0m / Invested Capital 472.3m)
WACC = 7.54% (E(511.2m)/V(732.4m) * Re(9.34%) + D(221.2m)/V(732.4m) * Rd(4.91%) * (1-Tc(0.31)))
Discount Rate = 9.34% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -51.11 | Cagr: -1.40%
[DCF] Terminal Value 73.10% ; FCFF base≈29.0m ; Y1≈25.4m ; Y5≈20.5m
[DCF] Fair Price = 2.84 (EV 329.2m - Net Debt 198.4m = Equity 130.8m / Shares 46.1m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -49.08 | EPS CAGR: -3.49% | SUE: -2.97 | # QB: -1
Revenue Correlation: 83.38 | Revenue CAGR: 1.14% | SUE: -0.81 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.10 | Chg30d=+5.56% | Revisions=+0% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.17 | Chg30d=-8.33% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=0.46 | Chg30d=-15.74% | Revisions=-25% | GrowthEPS=-39.3% | GrowthRev=-2.1%
EPS next Year (2027-12-31): EPS=0.69 | Chg30d=-18.71% | Revisions=-25% | GrowthEPS=+52.8% | GrowthRev=+5.6%
[Analyst] Revisions Ratio: -38% (up=1, down=4)